WHO Survey on ARV and Diagnostic Use
2012

Preliminary Results

Dr Vincent Habiyambere
HIV Technologies and Commodities Unit
HIV Department
Survey 2012

- 80 reporting L&MIC countries*
- 4.2 millions patients on ART
- Use of ARVs by end December 2011
- Analysis for 63 countries which have all details ART (4M): 93.65% adults vs 6.35% children

* 32 AFRO, 16 AMRO/PAHO, 14 EMRO, 4 EURO, 9 SEARO, 5 WPRO
First-line regimens used in adults in LMI countries (except America region) : 96.2% of adults on ART

- 44% used AZT,
- 31% used d4T,
- 24.3% TDF and
- 0.6 ABC

- 69.3% used NVP and 29.8% EFV and some PIs (LPVr)
Global evolution of major 1st line ART combinations* used in adults (2006-2012)

*12 countries which have been followed since 2006 and have complete report in all years: Burkina Faso, Burundi, Cambodia, Cameroun, Ethiopia, Kenya, Lesotho, Namibia, Nigeria, Uganda, Zambia, and Zimbabwe
Global evolution of d4T, AZT and TDF use in 1\textsuperscript{st} line therapy* (2006-2012)

*12 countries which have been followed since 2006 and have complete report in all years: Burkina Faso, Burundi, Cambodia, Cameroun, Ethiopia, Kenya, Lesotho, Namibia, Nigeria, Uganda, Zambia, and Zimbabwe
APIs evolution for adults 1st line, 2006 - 2012
Evolution of 1 and 2\textsuperscript{nd} line ART therapy in adults* (2006-2012)

Proportion of adults on 1st and 2nd line ART
2006 - 2012 (%)
Second-line regimens used in adults in LMI countries (except America region): 3.7% of adults on ART

Main second line regimens among adults (number of patients = 142361)

- AZT+3TC+TDF+LPV/r (5.8%)
- TDF+3TC+LPV/r (25.5%)
- TDF+FTC+LPV/r (15.5%)
- Other regimens (16.5%)
Global evolution of major 2\textsuperscript{nd} line ART combinations* used in adults (2006-2012)

*12 countries which have been followed since 2006 and have complete report in all years:
Burkina Faso, Burundi, Cambodia, Cameroun, Ethiopia, Kenya, Lesotho, Namibia, Nigeria, Uganda, Zambia, and Zimbabwe
Global evolution of PIs use in 2\textsuperscript{nd} line therapy* (2006-2012)

*12 countries which have been followed since 2006 and have complete report in all years:
Burkina Faso, Burundi, Cambodia, Cameroun, Ethiopia, Kenya, Lesotho, Namibia, Nigeria, Uganda, Zambia, and Zimbabwe
First-line regimens used in children in LMI countries (except America region): 94.4% of children on ART

Main first line regimens among children (number of patients = 245645)

- 60.9% used AZT
- 28.7% d4T
- 8.9% ABC
- 0.3% TDF
- 2.3% used LPV/r
Global evolution of major 1st line ART combinations used in children* (2006-2012)

*12 countries which have been followed since 2006 and have complete report in all years: Burkina Faso, Burundi, Cambodia, Cameroun, Ethiopia, Kenya, Lesotho, Namibia, Nigeria, Uganda, Zambia, and Zimbabwe
Second-line regimens used in children in LMI countries (except America region): 5.3% of children on ART

Main second line regimens among children (number of patients = 13713)

- 57.2% used ABC
- 30.6% used AZT
- 6.6% used TDF
- 87.6% used LPV/r
Global evolution of major 2nd line ART combinations used in children (2007-2012)*

Evolution of the main children second line regimens, 2006-2012

*12 countries which have been followed since 2006 and have complete report in all years:
Burkina Faso, Burundi, Cambodia, Cameroun, Ethiopia, Kenya, Lesotho, Namibia, Nigeria, Uganda, Zambia, and Zimbabwe
Global evolution of d4T, AZT and TDF use in 1st line therapy* (2006-2012)

*12 countries which have been followed since 2006 and have complete report in all years: Burkina Faso, Burundi, Cambodia, Cameroun, Ethiopia, Kenya, Lesotho, Namibia, Nigeria, Uganda, Zambia, and Zimbabwe
Global evolution of PIs use in 2nd line therapy* (2006-2012)

*12 countries which have been followed since 2006 and have complete report in all years: Burkina Faso, Burundi, Cambodia, Cameroun, Ethiopia, Kenya, Lesotho, Namibia, Nigeria, Uganda, Zambia, and Zimbabwe
### Distribution of APIs in adults & children (n=4,095,115)

<table>
<thead>
<tr>
<th>APIs (1st, 2nd &amp; salvage)</th>
<th>n</th>
<th>%</th>
<th>% by ARV Group</th>
<th>% (1st, 2nd &amp; salvage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3TC</td>
<td>3,622,787</td>
<td>29.6</td>
<td>44.3</td>
<td>88.5</td>
</tr>
<tr>
<td>d4T</td>
<td>1,219,419</td>
<td>10.0</td>
<td>14.9</td>
<td>29.8</td>
</tr>
<tr>
<td>AZT</td>
<td>1,824,418</td>
<td>14.9</td>
<td>22.3</td>
<td>44.6</td>
</tr>
<tr>
<td>TDF</td>
<td>983,920</td>
<td>8.0</td>
<td>12.0</td>
<td>24.0</td>
</tr>
<tr>
<td>ABC</td>
<td>72,376</td>
<td>0.6</td>
<td>0.9</td>
<td>1.8</td>
</tr>
<tr>
<td>ddI</td>
<td>20,781</td>
<td>0.2</td>
<td>0.3</td>
<td>0.5</td>
</tr>
<tr>
<td>FTC</td>
<td>435,592</td>
<td>3.6</td>
<td>5.3</td>
<td>10.6</td>
</tr>
<tr>
<td>NVP</td>
<td>2,748,283</td>
<td>22.4</td>
<td>70.7</td>
<td>67.1</td>
</tr>
<tr>
<td>EFV</td>
<td>1,140,660</td>
<td>9.3</td>
<td>29.3</td>
<td>27.9</td>
</tr>
<tr>
<td>ETV</td>
<td>39</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>LPV</td>
<td>166,398</td>
<td>1.4</td>
<td>95.9</td>
<td>4.1</td>
</tr>
<tr>
<td>NFV</td>
<td>447</td>
<td>0.0</td>
<td>0.3</td>
<td>0.0</td>
</tr>
<tr>
<td>IDV</td>
<td>3,949</td>
<td>0.0</td>
<td>2.3</td>
<td>0.1</td>
</tr>
<tr>
<td>SQV</td>
<td>1,141</td>
<td>0.0</td>
<td>0.7</td>
<td>0.0</td>
</tr>
<tr>
<td>ATV</td>
<td>1,414</td>
<td>0.0</td>
<td>0.8</td>
<td>0.0</td>
</tr>
<tr>
<td>FPV</td>
<td>251</td>
<td>0.0</td>
<td>0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>DRV</td>
<td>706</td>
<td>0.0</td>
<td>0.4</td>
<td>0.0</td>
</tr>
<tr>
<td>RGV</td>
<td>254</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>T20</td>
<td>0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>MVC</td>
<td>0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>12,242,835</td>
<td>100.0</td>
<td>299.0</td>
<td>299.0</td>
</tr>
</tbody>
</table>
THANK YOU